| 货号 | HB103036 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | BI-1206 |
|---|
| 生物活性 | BI-1206 (5 ug/mL, 0-5 h) blocks Rituximab (5 ug/mL)-induced and Rituximab-based combination with Ibrutinib or Venetoclax or CHOP-induced CD20 internalization effectively in JeKo-1 cells [1]. BI-1206 (10 mg/kg, i.v., twice a week) is highly potent in blocking tumor growth in Ibrutinib-Venetoclax dual resistant MCL PDX (PDX-A) NSG mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week) inhibits tumor growth when combined with Rituximab in Rituximab-Ibrutinib-CAR T-triple resistant MCL PDX (PDX-B) NSG mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week for 14 d) has better efficacy and prolonged survival in the triple combination group with Ibrutinib or Venetoclax compared to dual combinations without BI-1206 in JeKo-1 CDX mice model [1]. BI-1206 (10 mg/kg, i.v., twice a week) shows superior anti-tumor activity and prolonged survival when combined with Venetoclax compared to any single or dual combination in Ibrutinib-Rituximab-Venetoclax triple-resistant MCL PDX (PDX-C) model [1]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 靶标 | IGFR2, FCG2, Fc-gamma RII-b, CDw32, FcRII-b, IgG Fc receptor II-b, CD32, Fc-gamma-RIIb, Low affinity immunoglobulin gamma Fc region receptor II-b, FCGR2B |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | P31994 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | BI-1206, BI1206, BI1206 |
|---|
| 背景 | Low affinity immunoglobulin gamma Fc region receptor II-b (CD32b/FCGR2B) is a ~34 kDa protein. Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. |
|---|
| 文献 | 1. Jiang VC, et al., Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 Apr 11;15(1):42. [HB103036]
2. Changying Jiang, et al., BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma, Blood, Volume 134, Supplement 1, 2019, Page 2863, ISSN 0006-4971. [HB103036]
3. Mårtensson, L.et al., A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity with anti-HER2 therapy[J]. Cancer Research, 2022, 82(12_Supplement): 3423-3423. [HB103036] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
| Isotype Control | Human IgG1, lambda Isotype Control antibody (HyHEL-10) (HP248107) |
|---|
